¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© obO}NF*g^  
k^%2_ H  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #jBN?Z#  
  1¡¢Co-stimulators (or co-stimulating molecules) pLnB)z?  
  2¡¢NK-kB v8m`jxII64  
  3¡¢Immunoglobulin superfamily D^+?|Y@N  
  4¡¢antigen-presenting cell (APC) )1lu=gc  
  5¡¢death domain ^ q ?1U?4  
  6¡¢CCR and CXCR :_xh(W+2<  
  7¡¢Lectin (or mitogen) .IgRY\?Q  
  8¡¢Clusters of differentiation, CD) 'H|~u&?  
  9¡¢B7 family e"k/d<  
  10¡¢Cytotoxic T lymphocyte, CTL) ^2S# Uk  
  11¡¢IL-15 and IL-15 receptor (IL-15R) b*EXIzQ  
  12¡¢MHC restriction -:<lkq&/  
  13¡¢Affinity-chromatography /:Lu_)5   
  14¡¢Cyctosprin A, CsA _w!a`w*3  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) O("Uq../3  
D."=k{r.  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© BI/&dKM  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Nmp nJu|8  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ .tnkT;T  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ Elb aFbr  
pf& ag#nr  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© qf#)lyr<D6  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ (=u'sn:s  
  ѪҺ²¡Ñ§×¨Òµ£º pHC /(6?  
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»